ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1051

Rituximab for Interstitial Pneumonia with Autoimmune Features at Two Academic Medical Centers

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 1438

Rituximab Immunogenicity in ANCA-associated Vasculitis (RITUXIMAV)

Vasculitis – ANCA-Associated Poster

9:00AM-11:00AM: Abstract Number: 1050

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Sarcoidosis, Interstitial Lung Disease, & Inflammatory Eye Disease

9:00AM-11:00AM: Abstract Number: 1350

Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis from Two Phase 3 Trials

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1070

Scleromyositis Is Associated with Distinct Muscle Vasculopathic Features

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1069

Scleromyositis Is Associated with Nailfold Capillary Abnormalities Compared to Immune-Mediated Necrotizing Myopathy

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1018

Seasonal Variation in the Treat-to-Target Rate of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE): A Cohort Study on Self-reported Data from Smart System of Disease Management (SSDM)

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1366

Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1340

Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1374

Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1361

Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naïve Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study

Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

9:00AM-11:00AM: Abstract Number: 1243

Self-reported Fatigue in Patients with Primary Sjögren’s Syndrome Is Associated with an Objective Decline in Physical Performance and Symptoms of Pain and Depression

Sjögren’s Syndrome Poster

9:00AM-11:00AM: Abstract Number: 1080

Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1188

Serum Anti-malondialdehyde-acetaldehyde IgA Antibody Concentration Improves Prediction of Coronary Atherosclerosis Beyond Traditional Risk Factors in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

9:00AM-11:00AM: Abstract Number: 1200

Serum Anti-PAD4 and Anti-PAD3/4XR Antibodies in Rheumatoid Arthritis Associated-Interstitial Lung Disease Are Associated with Better Lung Function

RA – Diagnosis, Manifestations, & Outcomes Poster III: Cardiopulmonary Aspects

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].